Q-omics provides the consensus-scored CD70 profile across patient tissues and cancer cell-line models. CD70 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CD70 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CD70 RNA expression shows 12,922 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where CD70 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD70 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD70 survival associations across molecular data types. CD70 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD70 RNA expression–survival associations across cancer types. High CD70 expression shows unfavorable associations in MESO, UCS, UVM and LGG, but favorable associations in UCEC and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CD70 RNA expression.
This table summarizes CD70 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD70. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD70 shows higher tumor expression in KIRC, HNSC, KIRP, THCA, STAD and COAD. The KIRC box plot shows higher CD70 RNA expression in tumor versus normal tissue (log2 FC = +5.839, t-test p < 0.001).
This table shows molecular features associated with CD70 in patient tissues and cancer cell lines. In patient samples, CD70 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CD70 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
